![]() ![]() ![]() Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the world’s largest mining company, where her investment mandate was to help the decarbonization of BHP’s operations and to improve the sustainability of resource extraction. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Richard earned his doctorate in economics from the University of Southern California and his bachelor's and master's degrees from New York University.īrigid O’Brien joins RA Capital as a Managing Partner, Planetary Health. Before IVI, he was a consultant at the Analysis Group, assisting clients in the pharmaceutical industry with their value demonstration efforts at product launches. These research projects tested and operationalized novel approaches in stakeholder engagement, patient preference, economic modeling, and health equity. At IVI, he managed a portfolio of research projects and worked with leading researchers and multi-stakeholder advisory committees. ![]() Prior to joining RA, Richard served as Director of Research at the Innovation and Value Initiative (IVI), a non-profit research organization dedicated to advancing methods and practices of health technology assessment. Richard will be spearheading the effort to communicate our industry’s and portfolio companies’ value proposition to payors, policymakers, and society through comprehensive cost-effectiveness analyses and GCEA method development. Richard Xie is a Senior Health Economist at RA Capital. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Josh Resnick is a Senior Managing Director at RA Capital Management. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter also leads the firm’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |